183 related articles for article (PubMed ID: 36517634)
21. Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.
Tseng CS; Yang JH; Huang SW; Wang YJ; Chen CH; Pu YS; Cheng JC; Huang CY
BMC Cancer; 2023 Jun; 23(1):568. PubMed ID: 37340337
[TBL] [Abstract][Full Text] [Related]
22. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
23. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
[TBL] [Abstract][Full Text] [Related]
24. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
Thomsen FB; Røder MA; Rathenborg P; Brasso K; Borre M; Iversen P
Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983
[TBL] [Abstract][Full Text] [Related]
25. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
26. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
[TBL] [Abstract][Full Text] [Related]
27. Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.
Poon DMC; Wong KCW; Chan TW; Law K; Chan K; Lee EKC; Lee C; Chan M;
Clin Genitourin Cancer; 2018 Oct; 16(5):402-412.e1. PubMed ID: 30126765
[TBL] [Abstract][Full Text] [Related]
28. Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer.
Freedland SJ; Li S; Pilon D; Bhak RH; Narkhede S; Lefebvre P; Young-Xu Y
Curr Med Res Opin; 2021 Apr; 37(4):635-642. PubMed ID: 33571020
[TBL] [Abstract][Full Text] [Related]
29. A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
Payne H; Robinson A; Rappe B; Hilman S; De Giorgi U; Joniau S; Bordonaro R; Mallick S; Dourthe LM; Flores MM; Gumà J; Baron B; Duran A; Pranzo A; Serikoff A; Mott D; Herdman M; Pavesi M; De Santis M
Int J Cancer; 2022 Mar; 150(5):837-846. PubMed ID: 34648657
[TBL] [Abstract][Full Text] [Related]
30. Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
Fujimoto N; Minato A; Igawa T; Hiroshige T; Obara W; Fukuda A; Nagata Y; Mizushima Y; Tomisaki I; Harada K
Anticancer Res; 2022 Jun; 42(6):3041-3047. PubMed ID: 35641266
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.
Soleimani M; Zou K; Sunderland K; Struss W; Eigl BJ; Nappi L; Kollmannsberger CK; Finch D; Noonan K; Vergidis J; Zulfiqar M; Chi KN; Khalaf DJ
Eur J Cancer; 2021 Jul; 152():215-222. PubMed ID: 34130153
[TBL] [Abstract][Full Text] [Related]
32. Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab.
Hawkins CM; Barata PC; Cotogno P; Davis G; Jaeger E; Ledet E; Miller P; Lewis B; Sartor O; Layton J
Oncologist; 2023 Mar; 28(3):276-e158. PubMed ID: 36210487
[TBL] [Abstract][Full Text] [Related]
33. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.
Rescigno P; Dolling D; Conteduca V; Rediti M; Bianchini D; Lolli C; Ong M; Li H; Omlin AG; Schmid S; Caffo O; Zivi A; Pezaro CJ; Morley C; Olmos D; Romero-Laorden N; Castro E; Saez MI; Mehra N; Smeenk S; Sideris S; Gil T; Banks P; Sandhu SK; Sternberg CN; De Giorgi U; De Bono JS
Eur Urol Oncol; 2020 Apr; 3(2):176-182. PubMed ID: 31307958
[TBL] [Abstract][Full Text] [Related]
34. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
Armstrong AJ; Lin P; Tombal B; Saad F; Higano CS; Joshua AM; Parli T; Rosbrook B; van Os S; Beer TM
Eur Urol; 2020 Sep; 78(3):347-357. PubMed ID: 32527692
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Nagata Y; Matsukawa T; Tomisaki I; Fujimoto N
Anticancer Res; 2023 Jan; 43(1):429-436. PubMed ID: 36585210
[TBL] [Abstract][Full Text] [Related]
36. Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.
Lowentritt B; Pilon D; Khilfeh I; Rossi C; Muser E; Kinkead F; Waters D; Ellis L; Lefebvre P; Brown G
Urol Oncol; 2023 May; 41(5):253.e1-253.e9. PubMed ID: 37061452
[TBL] [Abstract][Full Text] [Related]
37. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
38. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
Armstrong AJ; Al-Adhami M; Lin P; Parli T; Sugg J; Steinberg J; Tombal B; Sternberg CN; de Bono J; Scher HI; Beer TM
JAMA Oncol; 2020 Feb; 6(2):217-225. PubMed ID: 31830211
[TBL] [Abstract][Full Text] [Related]
39. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?
Pereira-Salgado A; Kwan EM; Tran B; Gibbs P; De Bono J; IJzerman M
Eur Urol Focus; 2021 Jul; 7(4):752-763. PubMed ID: 32273196
[TBL] [Abstract][Full Text] [Related]
40. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.
van Nuland M; Bergman AM; Rosing H; de Vries N; Huitema ADR; Beijnen JH
Pharmacotherapy; 2019 Dec; 39(12):1137-1145. PubMed ID: 31596947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
